However, MEK inhibitors such as trametinib [69] and cobimetinib [70], whether used alone or in combination with chemotherapy, PI3K/mTOR inhibitors [71], EGFR inhibitors [72] and AKT inhibitors [73], have demonstrated limited clinical efficacy in patients with advanced CRC [67]. This evidence concerns the gene MAP2K7 and colorectal carcinoma.